| Characteristic . | Total . | Icosapent ethyl . | Placebo . | P . |
|---|---|---|---|---|
| . | (n = 47) . | (n = 22) . | (n = 25) . | . |
| . | Mean (SD) or count (%) . | Mean (SD) or count (%) . | Mean (SD) or count (%) . | . |
| Age, years | 57.1 (9.3) | 56.5 (9.9) | 57.6 (8.9) | 0.67 |
| Sex, male | 24 (51.1%) | 11 (50.0%) | 13 (52.0%) | 0.89 |
| Body mass index, kg/m2 | 32.0 (5.0) | 31.8 (4.5) | 32.2 (5.5) | 0.78 |
| Ethnicity, Hispanic | 25 (53.2%) | 11 (50.0%) | 14 (56.0%) | 0.68 |
| Race, white | 40 (85.1%) | 19 (86.4%) | 21 (84.0%) | 0.88 |
| Diabetes mellitus | 29 (61.7%) | 13 (59.1%) | 16 (64.0%) | 0.73 |
| Family history | 14 (29.8%) | 6 (27.3%) | 8 (32.0%) | 0.72 |
| Hypertension | 32 (68.1%) | 15 (68.2%) | 17 (68.0%) | 0.99 |
| Past smoking | 17 (36.2%) | 8 (36.4%) | 9 (36.0%) | 0.98 |
| Aspirin use | 20 (42.6%) | 9 (40.9%) | 11 (44.0%) | 0.83 |
| Characteristic . | Total . | Icosapent ethyl . | Placebo . | P . |
|---|---|---|---|---|
| . | (n = 47) . | (n = 22) . | (n = 25) . | . |
| . | Mean (SD) or count (%) . | Mean (SD) or count (%) . | Mean (SD) or count (%) . | . |
| Age, years | 57.1 (9.3) | 56.5 (9.9) | 57.6 (8.9) | 0.67 |
| Sex, male | 24 (51.1%) | 11 (50.0%) | 13 (52.0%) | 0.89 |
| Body mass index, kg/m2 | 32.0 (5.0) | 31.8 (4.5) | 32.2 (5.5) | 0.78 |
| Ethnicity, Hispanic | 25 (53.2%) | 11 (50.0%) | 14 (56.0%) | 0.68 |
| Race, white | 40 (85.1%) | 19 (86.4%) | 21 (84.0%) | 0.88 |
| Diabetes mellitus | 29 (61.7%) | 13 (59.1%) | 16 (64.0%) | 0.73 |
| Family history | 14 (29.8%) | 6 (27.3%) | 8 (32.0%) | 0.72 |
| Hypertension | 32 (68.1%) | 15 (68.2%) | 17 (68.0%) | 0.99 |
| Past smoking | 17 (36.2%) | 8 (36.4%) | 9 (36.0%) | 0.98 |
| Aspirin use | 20 (42.6%) | 9 (40.9%) | 11 (44.0%) | 0.83 |
| Characteristic . | Total . | Icosapent ethyl . | Placebo . | P . |
|---|---|---|---|---|
| . | (n = 47) . | (n = 22) . | (n = 25) . | . |
| . | Mean (SD) or count (%) . | Mean (SD) or count (%) . | Mean (SD) or count (%) . | . |
| Age, years | 57.1 (9.3) | 56.5 (9.9) | 57.6 (8.9) | 0.67 |
| Sex, male | 24 (51.1%) | 11 (50.0%) | 13 (52.0%) | 0.89 |
| Body mass index, kg/m2 | 32.0 (5.0) | 31.8 (4.5) | 32.2 (5.5) | 0.78 |
| Ethnicity, Hispanic | 25 (53.2%) | 11 (50.0%) | 14 (56.0%) | 0.68 |
| Race, white | 40 (85.1%) | 19 (86.4%) | 21 (84.0%) | 0.88 |
| Diabetes mellitus | 29 (61.7%) | 13 (59.1%) | 16 (64.0%) | 0.73 |
| Family history | 14 (29.8%) | 6 (27.3%) | 8 (32.0%) | 0.72 |
| Hypertension | 32 (68.1%) | 15 (68.2%) | 17 (68.0%) | 0.99 |
| Past smoking | 17 (36.2%) | 8 (36.4%) | 9 (36.0%) | 0.98 |
| Aspirin use | 20 (42.6%) | 9 (40.9%) | 11 (44.0%) | 0.83 |
| Characteristic . | Total . | Icosapent ethyl . | Placebo . | P . |
|---|---|---|---|---|
| . | (n = 47) . | (n = 22) . | (n = 25) . | . |
| . | Mean (SD) or count (%) . | Mean (SD) or count (%) . | Mean (SD) or count (%) . | . |
| Age, years | 57.1 (9.3) | 56.5 (9.9) | 57.6 (8.9) | 0.67 |
| Sex, male | 24 (51.1%) | 11 (50.0%) | 13 (52.0%) | 0.89 |
| Body mass index, kg/m2 | 32.0 (5.0) | 31.8 (4.5) | 32.2 (5.5) | 0.78 |
| Ethnicity, Hispanic | 25 (53.2%) | 11 (50.0%) | 14 (56.0%) | 0.68 |
| Race, white | 40 (85.1%) | 19 (86.4%) | 21 (84.0%) | 0.88 |
| Diabetes mellitus | 29 (61.7%) | 13 (59.1%) | 16 (64.0%) | 0.73 |
| Family history | 14 (29.8%) | 6 (27.3%) | 8 (32.0%) | 0.72 |
| Hypertension | 32 (68.1%) | 15 (68.2%) | 17 (68.0%) | 0.99 |
| Past smoking | 17 (36.2%) | 8 (36.4%) | 9 (36.0%) | 0.98 |
| Aspirin use | 20 (42.6%) | 9 (40.9%) | 11 (44.0%) | 0.83 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
